<DOC>
	<DOCNO>NCT01915628</DOCNO>
	<brief_summary>Prospective , multi-center registry conduct 6 Canadian interventional cardiology center . The e-BioMatrix data compare historical control group , Cypher arm Biosensors Leaders study consist 313 patient . All patient follow 2 year .</brief_summary>
	<brief_title>e-BioMatrix Canada Registry</brief_title>
	<detailed_description>The purpose registry capture additional `` on-label '' clinical data CE-marked BioMatrix Flex™ ( BA9™-Eluting ) stent system relation safety effectiveness . This prospective , multi-center registry enroll total 533 patient . The BioMatrix FlexTM study randomize controlled trial grant CE mark . The data review Health Canada randomize trial request . Prior marketing approval , Health Canada request registry implement provide data Canada 'on label patient ' supplement data already available Leaders trial , conduct 'all comer ' patient . The registry follow normal medical practice drug elute stent Canada . 100 % informed consent check , least Major Adverse Cardiac Events 2 year source data verify . All MACEs develop patient population adjudicate independent Clinical Events Committee . The patient follow clinically 2 year stent implantation . A third party Contract Research Organisation , Centre Innovative Medicine appoint perform site monitoring project management . The appropriate Data Management Validation , Statistical Analysis , Safety , Monitoring Plans guideline put place address quality consistency data . A Clinical Event Committee ( CEC ) put place registry , consist cardiologist participate registry . The mandate CEC review Major Adverse Cardiac Events ( MACE ) , adjudicate classify . In addition , order protect study participant , regular review report safety event sponsor Clinical Safety Officer weekly assessment incidence important risk pertain registry order detect safety signal . The site train Site Initiation Visits registry operation analysis activity , patient recruitment , data collection , data management , data analysis , report adverse event , change management .</detailed_description>
	<criteria>1 . Age ≥18 year 2 . Presence coronary artery stenosis one two native coronary artery 2.25 4.0 mm diameter cover one BioMatrix FlexTM stent 3 . Up two lesion two separate vessel treat 1 . Inability provide informed consent ; 2 . Life expectancy le 2 year ; 3 . Staged procedure plan within index procedure hospitalization ; 4 . ST elevation myocardial infarction ; 5 . Angiographic evidence thrombus ; 6 . EF &lt; 20 % ; 7 . Coronary artery bypass graftlesion incl SVG ; 8 . Chronic total occlusion target lesion ; 9 . In stent restenosis 10 . Bifurcation require 2 stent ; 11 . Left Main lesion ; 12 . Renal insufficiency ( serum creatinine &gt; 260 µmolmol/L &gt; 2.95mg/dl ) 13 . Multivessel disease two vessel affect ; 14 . Have know intolerance aspirin , clopidogrel , heparin , stainless steel , Biolimus A9 ( limus compound ) , contrast material ; 15 . Currently participate another study ; 16 . Planning surgery within 6 month ( exclude surgery DAPT maintain throughout perisurgical period ) ; 17 . Woman childbearing potential positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>MACE</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>On label</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Cardiac death</keyword>
	<keyword>TVR</keyword>
	<keyword>stent thrombosis</keyword>
</DOC>